Head-to-head evidence
DA-1726 vs mazdutide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1/glucagon receptor (dual) · full Obesity pipeline
DA-1726
Developed by MetaVia
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: November 2026 · NCT06252220 (registry estimate)
mazdutide
Developed by Eli Lilly and partners
NCT05607680 · Phase 3 · completed
The trial was randomized, blinded, and placebo-controlled with over 600 participants, and its primary endpoint was percent body-weight change, a disease-defining measure for obesity. Both mazdutide doses produced significantly greater weight loss than placebo (P<0.0001).
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: December 2026 · NCT06884293 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: DA-1726's landscape · mazdutide's landscape